Has David Mangels received payments from drug or device companies?

Yes. Drug and device makers reported $1,687 in general payments to David Mangels across 115 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Mangels did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Mangels come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Mangels

Gastroenterology · Cincinnati, OHNPI 1528057437

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 45.8% of the total. Reporting peaked in 2022 at $621 and has fallen 73.4% since, to $165 in 2023. That places this record below the midpoint for gastroenterology clinicians in OH, where the typical reported total is $2,203.

$1,687in general payments, 2019–2025

Across 115 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$772
Takeda Pharmaceuticals U.S.A., Inc.$213
Gilead$158
Ferring Pharmaceuticals Inc.$78
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$72
Pfizer$70
plus $324 from 10 others

What the payments were for

Food & beverage$1,687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	57	$772
Takeda Pharmaceuticals U.S.A., Inc.	14	$213
Gilead	9	$158
Ferring Pharmaceuticals Inc.	5	$78
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$72
Pfizer	4	$70
Johnson & Johnson	4	$60
Daiichi Sankyo Inc.	4	$59
Merck	3	$49
Bristol Myers Squibb	2	$39
UCB, Inc.	2	$35
Ironwood Pharmaceuticals, Inc	2	$33
Shionogi Inc	1	$16
Nestle Healthcare Nutrition Inc.	1	$15
Intercept Pharmaceuticals, Inc.	1	$13
Micro-tech Endoscopy USA, Inc.	1	$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Rinvoq$125

How this compares

$1,687 in reported general payments places this provider in the 40th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio →

Other gastroenterology in Cincinnati

Anita AfzaliCincinnati$798K
Kara de FeliceCincinnati$427K
Allan PeckCincinnati$391K
Ravi RavinuthalaCincinnati$302K
Robert IsfortCincinnati$162K
Luis LaraCincinnati$146K
Vidhya KunnathurCincinnati$96K
Moamen GabrCincinnati$70K
Lisa LestinaCincinnati$59K
Naim AlkhouriWestlake$1.9M

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →